Please assess the completion status of the following clinical trial:

Trial Title: Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Disease statue: NHL, HD, or MM that are chemorefractory or relapsed; CLL that is Rai Stage III/IV, or lymphocyte doubling time of 6 months, or stage I/II that is resistant to \> 2 chemotherapy regimens; AML or ALL in 1st or subsequent remission with poor prognostic features; CML in accelerated or blast phae; MDS with life-threatening cytopenias; patients who have had a previous autologous or allogeneic bone marrow or stem cell transplant; other hematologic disorders which allogeneic stem cell transplantation is appropriate where the risk of conventional transplantation is considered to be unacceptably high.~* Estimated disease-free survival of less than one year~* ECOG performance status of 0, 1, or 2~* HLA-genotypically or phenotypically matched (at A, B, DR loci) related donor~Exclusion Criteria:~* Patients who life expectancy is limited by diseases other than their hematologic malignancy.~* Cardiac Disease: symptomatic congestive hearth failure, or RVG, or ejection fraction of \< 45%, active angina pectoris, or uncontrolled hypertension.~* Pulmonary Disease: severe chronic obstructive lung disease, or symptomatic restrictive lung disease, or DLCO of \< 50%.~* Renal Disease: serum creatinine \> 2.0 mg/dl or creatinine clearance \< 50 ml/min.~* Hepatic Disease: serum bilirubin \> 2.0 mg/dl or alkaline phosphatase, SGOT or SGPT \> 3 times normal.~* Neurologic Disease: symptomatic leukoencephalopathy, active CNS malignancy or other neuropsychiatric abnormalities believed to preclude transplantation~* HIV or HTLV I antibody or Hepatitis B surface antigen positivity~* Uncontrolled infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Transplantation (Type: EXPERIMENTAL): T-cell depleted HLA-matched peripheral blood stem cell transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).